Contribution of endothelium-derived hyperpolarizing factors to the regulation of vascular tone in humans

Fundamental and Clinical Pharmacology

Volumn 22, Issue 4, 2008, Pages 363-377

  Bellien, Jeremy ^a   Thuillez, Christian ^a   Joannides, Robinson ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Endothelium; Endothelium derived hyper polarizing factor; Epoxyeicosatrienoic acids; Vascular pharmacology

Indexed keywords

APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CATALASE; CHARYBDOTOXIN; CLOTRIMAZOLE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; FLUCONAZOLE; HYDROGEN PEROXIDE; IBERIOTOXIN; LERCANIDIPINE; LISINOPRIL; MICONAZOLE; NITRIC OXIDE; PERINDOPRILAT; POTASSIUM ION; PROSTACYCLIN; SULFAPHENAZOLE; TETRABUTYLAMMONIUM; TETRYLAMMONIUM; BIOLOGICAL FACTOR; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; ICOSANOID;

BLOOD VESSEL TONE; BRAIN BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY; ENDOTHELIAL DYSFUNCTION; GAP JUNCTION; HOMEOSTASIS AND REGULATION; HUMAN; MESENTERY BLOOD FLOW; MUSCLE FIBER MEMBRANE POTENTIAL; PERIPHERAL CIRCULATION; PERIPHERAL VEIN; POLARIZATION; PRIORITY JOURNAL; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; REVIEW; SKIN BLOOD VESSEL; SPLANCHNIC BLOOD FLOW; VASODILATATION; CELL JUNCTION; DRUG EFFECT; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

BIOLOGICAL FACTORS; EICOSANOIDS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GAP JUNCTIONS; HUMANS; HYDROGEN PEROXIDE; NITRIC OXIDE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; VASCULAR RESISTANCE;

EID: 55949129040     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00610.x     Document Type: Review

References (108)

1. Widlansky M.E., Gokce N., Keaney J.F. Jr., Vita J.A. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. (2003) 42 1149-1160.
2. Quyyumi A.A. Prognostic value of endothelial function. Am. J. Cardiol. (2003) 91 19H-24H.
3. Lerman A., Zeiher A.M. Endothelial function. Cardiac events. Circulation (2005) 111 363-368.
4. Joannides R., Bellien J., Thuillez C. Clinical methods for the evaluation of endothelial function - a focus on resistance arteries. Fundam. Clin. Pharmacol. (2006) 20 311-320.
5. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 2 997-1000.
6. Joannides R., Haefeli W., Linder L. et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 91 1314-1319.
7. Celermajer D.S., Sorensen S.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 340 1111-1115.
8. Moncada S., Gryglewski R.J., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substances that inhibits platelet aggregation. Nature (1976) 263 663-665.
9. Johnson R.A., Morton D.R., Kinner J.H. et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 12 915-928.
10. Duffy S.J., Castle S.F., Harper R.W., Meredith I.T. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation (1999) 100 1951-1957.
11. Sun D., Liu H., Yan C. et al. COX-2 contributes to the maintenance of flow-induced dilation in arterioles of eNOS knockout mice. Am. J. Physiol. Heart Circ. Physiol. (2006) 291 H1429-H1435.
12. Feletou M., Vanhoutte P.M. Endothelium-dependent hyper-polarization of canine coronary smooth muscle. Br. J. Pharmacol. (1988) 93 515-524.
13. Taylor S.G., Weston A.H. Endothelium-derived hyperpolariz-ing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol. Sci. (1988) 9 272-274.
14. Chen G., Suzuki H., Weston A.H. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rats blood vessels. Br. J. Pharmacol. (1988) 95 1165-1174.
15. Garland C.J., Plane F., Kemp B.K., Cocks T.M. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol. Sci. (1995) 6 23-30.
16. MacGuire J.J., Ding H., Triggle C.R. Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolariz-ing factor(s). Can. J. Physiol. Pharmacol. (2001) 79 443-470.
17. Busse R., Edwards G., Feletou M., Fleming I., Vanhoutte P.M., Weston A.H. EDHF: bringing the concepts together. Trends Pharmacol. Sci. (2000) 23 374-380.
18. Feletou M., VanHoutte P.M. EDHF: the Complete Story. CRC Taylor and Francis, Boca Raton, 2006, pp 1-298.
19. Feletou M., VanHoutte P.M. Endothelium-derived hyper-polarizing factor. Where are we now? Arterioscler. Thromb. Vasc. Biol. (2006) 26 1215-1225.
20. Fleming I. Cytochrome P450 epoxygenase as EDHF syn-thase(s). Pharmacol. Res. (2004) 49 525-533.
21. 2+ signaling and hyperpolarization in endothelial cells. Arterioscler. Thromb. Vasc. Biol. (2007) 27 2612-2618.
22. Nagao T., Illiano S., Vanhoutte P.M. Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats. Am. J. Physiol. (1992) 263 H1090-H1094.
23. Sandow S.L., Hill C.E. Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolar-izing factor-mediated responses. Circ. Res. (2000) 86 341-346.
24. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation (1996) 64 3341-3347.
25. Larsen B.T., Campbell W.B., Gutterman D.D. Beyong vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol. Sci. (2007) 28 32-38.
26. Nakashima M., Mombouli J.V., Taylor A.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization caused by brady-kinin in human coronary arteries. J. Clin. Invest. (1993) 92 2867-2871.
27. Shiode N., Morishima N., Nakayama K., Yamagata T., Matsuura H., Kajiyama G. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. J. Am. Coll. Cardiol. (1996) 27 304-310.
28. Dube S., Canty J.M. Jr. Shear stress-induced vasodilatation in porcine coronary conduit arteries is independent of nitric oxide release. Am. J. Physiol. Heart Circ. Physiol. (2001) 280 H2581-H2590.
29. Tousoulis D., Davies G.J., Tentolouris C., Crake T., Lefroy D.C., Toutouzas P. Effects of inhibition of nitric oxide synthesis patients with coronary artery disease and stable angina. Eur. Heart J. (1997) 18 608-613.
30. Kemp B.K., Cocks T.M. Evidence that mechanisms dependent and independent of nitric oxide mediate endothelium-dependent relaxation to bradykinin in human small resistance-like coronary arteries. Br. J. Pharmacol. (1997) 120 757-762.
31. Davisson R.L., Shaffer R.A., Johnson A.K., Lewis S.J. Use-dependent loss of active sympathetic neurogenic vasodilation after nitric oxide synthase inhibition in conscious rats. Evidence for the presence of preformed stores of nitric oxide-containing factors. Hypertension (1996) 28 347-353.
32. Batenburg W.W., Garrelds I.M., van Kats J.P., Saxena P.R., Danser A.H. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension (2004) 43 488-492.
33. + channels. Circulation (2001) 103 1992-1998.
34. Miura H., Bosnjak J.J., Saito T., Miura M., Gutterman D.D. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ. Res. (2003) 92 e31-e40.
35. Liu Y., Zhao H., Li H., Kalyanaraman B., Nicolosi A.C., Gutterman D.D. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ. Res. (2003) 93 573-580.
36. + channels. Circ. Res. (1998) 83 501-507.
37. Larsen B.T., Miura H., Hatoum O.A. et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. (2006) 290 H491-H499.
38. Nishikawa Y., Ogawa S. Importance of nitric oxide in the coronary artery at rest and during pacing in humans. J. Am. Coll. Cardiol. (1997) 29 85-92.
39. Petersson J., Zygmunt P.M., Hogestatt E.D. Characterization of the potassium channels involved in EDHF-mediated relaxation in cerebral arteries. Br. J. Pharmacol. (1997) 120 1344-1350.
40. Golding E.M., Marrelli S.P., You J., Bryan R.M. Jr. Endothelium-derived hyperpolarizing factor in the brain: a new regulator of cerebral blood flow? Stroke (2002) 33 661-663.
41. Andresen J., Shafi N.I., Bryan R.M. Jr Endothelial influences on cerebrovascular tone. J. Appl. Physiol. (2006) 100 318-327.
42. You J., Golding E.M., Bryan R.M. Arachidonic acid metabolites, hydrogen peroxide, and EDHF in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. (2005) 289 H1077-H1083.
43. + in endothelium-derived hyperpolarizing factor-linked dilatation in rat middle cerebral artery. Stroke (2005) 36 1526-1532.
44. Urakami-Harasawa L., Shimokawa H., Nakashima M., Egashira K., Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J. Clin. Invest. (1997) 100 2793-2799.
45. Wallerstedt S.M., Bodelsson M. Endothelium-dependent relaxation by substance P in human isolated omental arteries and veins: relative contribution of prostanoids, nitric oxide and hyperpolarization. Br. J. Pharmacol. (1997) 120 25-30.
46. Ohlmann P., Martínez M.C., Schneider F., Stoclet J.C., Andri-antsitohaina R. Characterization of endothelium-derived relaxing factors released by bradykinin in human resistance arteries. Br. J. Pharmacol. (1997) 121 657-664.
47. Matoba T., Shimokawa H., Kubota H. et al. Hydrogen peroxide is an EDHF in human mesenteric arteries. Bioch. Biophys. Res. Commun. (2002) 290 909-913.
48. Morikawa K., Fujiki T., Matoba T. et al. Important role of superoxide dismutase in EDHF-mediated responses of human mesenteric arteries. J. Cardiovasc. Pharmacol. (2004) 44 552-556.
49. Hatoum O.A., Binion D.G., Miura H., Telford G., Otterson M.F., Gutterman D.D. Role of hydrogen peroxide in ACh-induced dilation of human submucosal intestinal microvessels. Am. J. Physiol. Heart Circ. Physiol. (2005) 288 H48-H54.
50. Honing M.L.H., Smits P., Morrison P.J., Rabelink T.J. Brady-kinin-induced vasodilatation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension (2000) 35 1314-1318.
51. Inokuchi K., Hirooka Y., Shimokawa H. et al. Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertension (2003) 42 919-924.
52. Bellien J., Joannides R., Iacob M., Arnaud P., Thuillez C. Calcium-activated potassium channels and nitric oxide regulate human peripheral conduit artery mechanics. Hypertension (2005) 46 210-216.
53. Bellien J., Joannides R., Iacob M., Thuillez C. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am. J. Physiol. Heart Circ. Physiol. (2006) 290 H1347-H1352.
54. Robinson B.F., Phillips R.J., Wilson P.N., Chiodini P.L. Effect of local infusion of ouabain on human forearm vascular resistance and on response to potassium, verapamil and sodium nitroprusside. J. Hypertens. (1983) 1 165-169.
55. Dawes M., Sieniawska C., Delves T., Dwivedi R., Chowienczyk P.J., Ritter J.M. Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm. Circulation (2002) 105 1323-1328.
56. + channels (KIR) inhibits bradykinin-induced vasodilatation in human forearm resistance vascula-ture. Arterioscler. Thromb. Vasc. Biol. (2005) 25 e7-e9.
57. Woolfson R.G., Benjamin N., Todd S.D., Poston L., Ritter J.M. Ouabain and responses to endothelium-dependent vasodilators in the human forearm. Br. J. Clin. Pharmacol. (1991) 32 758-560.
58. Taddei S., Ghiadoni L., Virdis A., Buralli S., Salvetti A. Vasodilatation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation (1999) 100 1400-1405.
59. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (2003) 41 950-955.
60. Halcox J.P.J., Narayanan S., Cramer-Joyce L., Mincemoyer R., Quyyumi A.A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol. Heart Circ. Physiol. (2001) 280 H2470-H2477.
61. Alvarez J., Montero M., Garcia-Sancho J. High affinity inhibition of Ca(2 +)-dependent K+ channels by cytochrome P-450 inhibitors. J. Biol. Chem. (1992) 267 11789-11793.
62. Hillig T., Krustrup P., Fleming I., Osada T., Saltin B., Hellsten Y. Cytochrome P450, 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J. Physiol. (2003) 546 307-314.
63. Passauer J., Bussemaker E., Lassig G. et al. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin. Sci. (Lond) (2003) 105 513-518.
64. Fichtlscherer S., Dimmeler S., Breuer S., Busse R., Zeiher A.M., Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation (2004) 109 178-183.
65. Passauer J., Pistrosch F., Lassig G. et al. Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney Int. (2005) 67 1907-1912.
66. Taddei S., Versari D., Cipriano A. et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J. Am. Coll. Cardiol. (2006) 28 508-515.
67. Fleming I., Michaelis U.R., Bredenkotter D. et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. (2001) 88 44-51.
68. Honing M.L., Smits P., Morrison P.J., Burnett J.C., Rabelink T.J. C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension (2001) 37 1179-1183.
69. Popp R., Fleming I., Busse R. Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor. A modulator of arterial compliance. Circ. Res. (1998) 82 696-703.
70. Goto K., Fujii K., Kansui Y., Iida M. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors. Clin. Exp. Pharmacol. Physiol. (2004) 31 650-655.
71. Bussemaker E., Popp R., Fisslthaler B. et al. Aged spontaneously hypertensive rats exhibit a selective loss of EDHF-mediated relaxation in the renal artery. Hypertension (2003) 42 562-568.
72. Katz S.D., Krum H. Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarzing factor. Am. J. Cardiol. (2001) 87 1089-1092.
73. Hamilton C.A., Williams R., Pathi V. et al. Pharmacological characterization of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc. Res. (1999) 42 214-223.
74. Liu Z.G., Ge Z.D., He G.W. Difference in endothelium-derived hyperpolarizing factor-mediated hyperpolarization and nitric oxide release between human internal mammary artery and saphenous vein. Circulation (2000) 102 III296-III301.
75. He G.W., Liu Z.G. Comparison of nitric oxide release and endothelium-derived hyperpolarizing factor-mediated hyper-polarization between human radial and internal mammary arteries. Circulation (2001) 104 I344-I1349.
76. Archer S.L., Gragasin F.S., Wu X. et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12- epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation (2003) 107 769-776.
77. Hamilton C.A., McPhaden A.R., Berg G., Pathi V., Dominiczak A.F. Is hydrogen peroxide an EDHF in human radial arteries? Am. J. Physiol. Heart Circ. Physiol. (2001) 280 H2451-H2455.
78. Mullen M.J., Kharbanda R.K., Cross J. et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo. Circ. Res. (2001) 88 145-151.
79. Bellien J., Iacob M., Gutierrez L. et al. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension (2006) 48 1088-1094.
80. Fischer D., Landmesser U., Spiekermann S. et al. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur. J. Heart Fail. (2007) 9 770-775.
81. Bellien J., Iacob M., Eltachaninoff H., Bourkaib R., Thuillez C., Joannides R. Angiotensin II type 1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NO-synthase inhibition, din. Sci. (Lond) (2007) 112 393-401.
82. Kessler P., Lischke V., Hecker M. Etomidate and thiopental inhibit the release of endothelium-derived hyperpolarizing factor in the human renal artery. Anesthesiology (1996) 84 1485-1488.
83. Bussemaker E., Popp R., Binder J., Busse R., Fleming I. Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery. Kidney Int. (2003) 63 1749-1755.
84. Rittenhouse A.R., Parker C., Brugnara C., Morgan K.G., Alper S.L. Inhibition of maxi-K currents in ferret portal vein smooth muscle cells by the antifungal clotrimazole. Am. J. Physiol. (1997) 273 C45-C56.
85. Maier K.G., Roman R.J. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr. Opin. Nephrol. Hypertens. (2001) 10 81-87.
86. Imig J.D. Eicosanoids and renal vascular function in diseases. Clin. Sci. (Lond) (2006) 111 21-34.
87. Buus N.H., Simonsen U., Pilegaard H.K., Mulvany M.J. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br. J. Pharmacol. (2000) 129 184-192.
88. McIntyre C.A., Buckley C.H., Jones G.C. et al. Endothelium-derived hyperpolarizing factor and potassium use different mechanisms to induce relaxation of human subcutaneous resistance arteries. Br. J. Pharmacol. (2001) 133 902-908.
89. Coats P., Johnston F., MacDonald J., McMurray J.J., Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation (2001) 103 1702-1708.
90. Lang N.N., Luksha L., Newby D.E., Kublickiene K. Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. Am. J. Physiol. Heart Circ. Physiol. (2007) 292 H1026-H1032.
91. Kellogg D.L., Liu Y., Kosiba I.F., O'Donnell D. Role of nitric oxide in the vascular effects of local warming of the skin in humans. J. Appl. Physiol. (1999) 86 1185-1190.
92. Kvandal P., Landsverk S.A., Bernjak A., Stefanovska A., Kvernmo H.D., Kirkeboen K.A. Low-frequency oscillations of the laser Doppler perfusion signal in human skin. Microvasc. Res. (2006) 72 120-127.
93. Lorenzo S., Minson C. Human cutaneous reactive hyperaemia: role of BKCa channels and sensory nerves. J. Physiol. (2007) 585 295-303.
94. + channels mediate relaxation of forearm veins in chronic renal failure. J. Hypertens. (2003) 21 1927-1934.
95. Strobel W.M., Luscher T.F., Simper D., Linder L., Haefeli W.E. Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action. Clin. Pharmacol. Ther. (1996) 60 435-443.
96. Yang J.A., He G.W. Surgical preparation abolishes endothelium-derived hyperpolarizing factor-mediated hyperpolarization in the human saphenous vein. Ann. Thorac. Surg. (1997) 63 429-433.
97. Brakemeier S., Kersten A., Eichler I. et al. Shear stress-induced up-regulation of the intermediate-conductance Ca(2 +)-acti-vated K(+) channel in human endothelium. Cardiovasc. Res. (2003) 60 488-496.
98. Moroe H., Fujii H., Honda H. et al. Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. Eur. J. Pharmacol. (2004) 497 317-325.
99. Angulo J., Cuevas P., Fernandez A. et al. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem. Biophys. Res. Commun. (2003) 312 1202-1208.
100. Kenny L.C., Baker P.N., Kendall D.A., Randall M.D., Dunn W.R. Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Clin. Sci. (Lond) (2002) 103 67-73.
101. Fisslthaler B., Michaelis U.R., Randriamboavonjy V., Busse R., Fleming I. Cytochrome P450 epoxygenase and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochem. Biophys. Acta. (2003) 1619 332-339.
102. Bertrand-Thiebault C., Masson C., Siest G., Batt A.M., Visvikis-Siest S. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. J. Cardiovasc. Pharmacol. (2007) 49 306-315.
103. Fisslthaler B., Hinsch N., Chataigneau T. et al. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension (2000) 36 270-275.
104. Zhao X., Quigley J.E., Yuan J., Wang M.H., Zhou Y., Imig J.D. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. (2006) 290 H2187-H1295.
105. Dessy C., Moniotte S., Ghisdal P., Havaux X., Noirhomme P., Balligand J.L. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation (2004) 110 948-954.
106. Loch D., Hoey A., Morisseau C., Hammock B.O., Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. (2007) 47 87-98.
107. Zhang W., Koerner I.P., Noppens R. et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. Cereb. Blood. Flow Metab. (2007) 27 1931-1940.
108. Seubert J.M., Sinal C.J., Graves J. et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. (2006) 99 442-450.